Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 2/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.34 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.31 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.31 |
| ▸ | AKT1 | P31749 | 2/20 | 0.31 |
| ▸ | AKT2 | P31751 | 2/20 | 0.31 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199322 | 0.93 | TLR4 (0.44) | TLR4LPAR1LPAR3ENPP2SLC2A1 | |
| SCHEMBL4198240 | 0.92 | TLR4 (0.46) | TLR4SMPD1LPAR1LPAR3ENPP2 | |
| SCHEMBL4201319 | 0.91 | TLR4 (0.50) | TLR4LPAR3ENPP2NR5A2NR5A1 | |
| SCHEMBL4195266 | 0.91 | TLR4 (0.50) | TLR4LPAR3ENPP2NR5A2NR5A1 | |
| SCHEMBL4201320 | 0.91 | TLR4 (0.50) | TLR4LPAR3ENPP2NR5A2NR5A1 | |
| SCHEMBL4208978 | 0.91 | TLR4 (0.44) | TLR4SMPD1LPAR1LPAR3ENPP2 | |
| SCHEMBL12371535 | 0.89 | TLR4 (0.44) | TLR4SMPD1AKT1AKT2AKT3 | |
| SCHEMBL4203283 | 0.88 | TLR4 (0.49) | TLR4 | |
| SCHEMBL4205271 | 0.88 | TLR4 (0.49) | TLR4 | |
| SCHEMBL4203280 | 0.88 | TLR4 (0.49) | TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1702926-A1 | LEVULOSE GLUCOSELIPID A ANALOGUE | Sankyo Company, Limited (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SLC2A3, GPR119, SLC2A2 | TLR4 294/4885SMPD1 348/4885LPAR1 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.